Onco advances cancer therapy development phase

Onco-Innovations Limited announced a new milestone in the development of its cancer treatment platform, confirming that its research partner, Nucro-Technics Inc., has launched advanced bioanalytical work in support of the company’s ongoing preclinical studies.

The Toronto-based contract research organization is collaborating with Onco on the development of A83B4C63, the active pharmaceutical ingredient connected to the company’s exclusively licensed PNKP inhibitor technology. The latest phase focuses on supporting a non-GLP pharmacokinetic and biodistribution animal model study, a critical step in evaluating how the compound behaves inside the body.

According to the company, Nucro-Technics has begun developing and implementing specialized liquid chromatography-mass spectrometry (LC-MS) analytical methods required to measure the compound in biological samples generated during testing. These analytical techniques are intended to provide researchers with detailed insight into the drug candidate’s exposure levels, distribution patterns, and overall therapeutic potential.

The company described the work as an important progression in moving the technology from early-stage discovery toward becoming a development-ready therapeutic candidate.

“The initiation of this analytical phase gives us the capability to generate the data that truly drives decision-making in early drug development. It allows us to understand how our PNKP inhibitor behaves in vivo and ensures that each subsequent study is grounded in high-quality evidence. This is the type of foundational work that moves a program from concept toward a real clinical candidate,” said Thomas O’Shaughnessy, CEO of Onco-Innovations.

The analytical phase is expected to help refine dosing strategies, support formulation development, and prepare the company for future GLP-compliant studies as part of its broader IND-enabling program.

Nucro-Technics will continue conducting method development and non-GLP analyses while delivering reports aligned with the project’s operational timeline. The collaboration is designed to support Onco’s long-term objective of advancing the technology toward clinical evaluation and expanding its portfolio of DNA Damage Response Inhibitor (DDRi) therapies.

Onco-Innovations, based in Canada, focuses on oncology research and the development of cancer treatments targeting solid tumors. The company says its mission centers on advancing cancer prevention and treatment through research-driven therapeutic innovation.

The announcement comes as biotechnology companies continue increasing investment in precision oncology and DNA damage response therapies, a rapidly growing area of cancer drug development aimed at targeting weaknesses in tumor cells while minimizing damage to healthy tissue.

The company also included a standard forward-looking statement caution, noting that future development results remain subject to scientific, operational, and regulatory risks.